GoodRx (GDRX) Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last year. There are currently 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GDRX, but not buy additional shares or sell existing shares.
View GDRX analyst ratings or view top-rated stocks.

13 analysts have issued 12-month target prices for GoodRx's stock. Their GDRX share price forecasts range from $5.00 to $12.00. On average, they anticipate the company's share price to reach $7.73 in the next twelve months. This suggests that the stock has a possible downside of 2.6%.
View analysts price targets for GDRX or view top-rated stocks among Wall Street analysts.

GoodRx's stock was trading at $4.66 at the beginning of the year. Since then, GDRX shares have increased by 70.4% and is now trading at $7.94.
View the best growth stocks for 2023 here.

GoodRx Holdings, Inc. (NASDAQ:GDRX) posted its quarterly earnings results on Wednesday, November, 10th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.08. The firm had revenue of $195.10 million for the quarter, compared to analyst estimates of $196.08 million. GoodRx had a negative net margin of 6.48% and a positive trailing twelve-month return on equity of 1.53%. During the same period in the prior year, the business posted ($0.25) EPS.

ETFs with the largest weight of GoodRx (NASDAQ:GDRX) stock in their portfolio include Invesco Dynamic Media ETF (PBS), WisdomTree Growth Leaders Fund (PLAT) and Global X Telemedicine & Digital Health ETF (EDOC).IQ Chaikin U.S. Small Cap ETF (CSML).

GoodRx issued an update on its second quarter 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $185.00 million-$188.00 million, compared to the consensus revenue estimate of $191.68 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX).

(GDRX) raised $900 million in an initial public offering (IPO) on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

GoodRx trades on the NASDAQ under the ticker symbol "GDRX."

GoodRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.31%), Assenagon Asset Management S.A. (0.30%), Bank of New York Mellon Corp (0.04%), Swiss National Bank (0.04%), Janney Montgomery Scott LLC (0.02%) and New York Life Investment Management LLC (0.02%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Lake Group LLC Silver and Trevor Bezdek.
View institutional ownership trends.

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GDRX stock can currently be purchased for approximately $7.94.

GoodRx (NASDAQ:GDRX) has a market capitalization of $3.15 billion and generates $747.21 million in revenue each year. The company earns $-32,830,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

The company employs 952 workers across the globe.

GoodRx's mailing address is 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401. The official website for the company is www.goodrx.com. The company can be reached via phone at 855-268-2822 or via email at alex@blueshirtgroup.com.